Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral®) at day 7 post-renal transplantation and incidence of rejection in the first month

Therapeutic Drug Monitoring

Volumn 24, Issue 4, 2002, Pages 479-486

  Morris, Raymond G ^a   Russ, Graeme R ^a   Cervelli, Matthew J ^a   Juneja, Rajiv ^a   McDonald, Stephen P ^a   Mathew, Timothy H ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Cyclosporine; Therapeutic drug monitoring; Transplantation

Indexed keywords

CORAS; CYCLOSPORIN A; DILTIAZEM; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANAFCORTELONE; PREDNISOLONE;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL;

AREA UNDER CURVE; CYCLOSPORINE; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036334289     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200208000-00003     Document Type: Article

References (55)

1. Performance and specificity of monoclonal immunoassays for cyclosporin monitoring: How specific is specific?
2. Comparison of cyclosporine measurement in whole blood by high performance liquid chromatography, monoclonal fluorescence polarisation immunoassay and monoclonal enzyme multiplied immunoassay
3. Cyclosporin whole blood immunoassay (AxSYM, CEDIA, and EMIT); a critical overview of performance characteristics and comparison with HPLC
4. Selection of an optimal assay method for monitoring of cyclosporin therapy
5. Comparative analyses of cyclosporin in whole blood and plasma by radioimmunoassy, fluorescence polarisation immunoassay and high pressure liquid chromatography
6. Specific EMIT and FPIA assays for cyclosporin compared with Cyclotrac 125I-RIA
7. Evaluation of the new AxSYM cyclosporine assay: Comparison with TDx monoclonal whole blood and EMIT cyclosporine assays
8. Canadian consensus meeting on cyclosporine monitoring: Report of the consensus panel
9. Lake Louise consensus meeting on cyclosporin monitoring in organ transplantation: Report of the consensus panel
10. Survey of cyclosporin therapeutic ranges, assay methodology and use of 'sparing agents' in Australasian transplant centres
11. Cyclosporin-A monitoring in Australia: Consensus recommendations
12. Consensus Document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine
13. Critical issues in cyclosporin monitoring: Report of the task force on cyclosporin monitoring
14. Clinical correlations of cyclosporin HPLC and FPIA levels in renal transplant recipients
15. Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring
16. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation
17. Area under curve monitoring of cyclosporin therapy: The early post-transplant period
18. Trough levels and concentration time curves of cyclosporin in patients undergoing renal transplantation
19. The ability of pretransplant test dose pharmacokinetic profiles to reduce early adverse events after renal transplantation
20. Challenges in cyclosporine therapy; the role of therapeutic monitoring by area under the curve monitoring
21. Optimisation of cyclosporin therapy in renal transplantation by a pharmacokinetic strategy
22. Specific monoclonal radioimmunoassay for trough concentration and AUC-monitoring of cyclosporin in renal transplantation
23. Cyclosporin plasma levels six hours after oral administration: A useful tool for monitoring therapy
24. A limited sampling strategy for the measurement of cyclosporine AUC
25. Cyclosporine monitoring in patients with renal transplants: Two- or three-point methods that estimate area under the curve are superior to troughs in predicting drug exposure
26. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients
27. Optimization of cyclosporin therapy with new therapeutic drug monitoring strategies
28. Neoral monitoring by simplified sparse sampling area under the concentration-time curve
29. Absorption profiling of cyclosporine therapy de novo kidney transplantation: A prospective, randomised study comparing sparse sampling to trough monitoring
30. Neoral absorption profiling: An evolution in effectiveness
31. Methods for clinical monitoring of cyclosporin in transplant patients
32. Cyclosporin monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring
33. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporin therapy in de novo renal transplant patients treated with Sandimmune or Neoral
34. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period
35. Predicting patients' exposure to cyclosporin
36. Pharmacokinetic validation of Neoral absorption profiling
37. Improved clinical outcomes for liver transplant recipients using cyclosporin blood level monitoring based on two-hour post-dose levels
38. Clinical benefit of Neoral dose monitoring with cyclosporin 2-hr post-dose levels compared with trough levels in a stable heart transplant patients
39. Peak cyclosporin levels (Cmax) correlate with freedom from liver graft rejection
40. Two hour cyclosporin level determination is the appropriate tool to monitor Neoral therapy
41. The temporal profile of calcineurin inhibition by cyclosporine in vivo
42. Stimulated response of peripheral lymphocytes may distinguish cyclosporin effect in renal transplant recipients receiving a cyclosporin+rapamycin regimen
43. Neural monitoring: Limitations of trough level monitoring and the potential role of limited sampling strategies
44. The use of other drugs to allow a lower dosage of cyclosporin to be used
45. Study of Neoral kinetics in adult renal transplantation treated with diltiazem
46. Formulation of diltiazem affects cyclosporin-sparing activity
47. Associations between use of cyclosporin sparing agents and outcome in kidney transplant recipients
48. Dose-dependent effect of cyclosporin on renal arterial resistance in dogs
49. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients
50. A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant
51. Immunoassays in comparison to LC-MS/MS, is there a difference between trough (C0) and C2 levels?
52. Cyclosporin monitoring - State of the art?
53. Rapid liquid chromatography-tandem mass spectrometry method for routine analysis of cyclosporin A over an extended concentration range
54. Diltiazem increases the blood concentrations of cyclised cyclosporine metabolites resulting in different cyclosporine metabolite pattern in stable male and female renal allograft recipients
55. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors